Activity and resistance of trastuzumab according to different clinical settings

Elda Tagliabue, Manuela Campiglio, Serenella M. Pupa, Sylvie Ménard, Andrea Balsari

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Trastuzumab, a humanized monoclonal antibody directed against HER2, has shown efficacy in breast cancers; however many patients do not respond to this reagent. Here, we discuss the potential mechanisms of trastuzumab efficacy and resistance in different clinical settings as a step toward optimizing the appropriate application of this antibody.The three major antitumor mechanisms of trastuzumab, i.e., inhibition of proliferation, antibody-dependent cell cytotoxicity (ADCC) and inhibition of DNA repair, appear to be differentially operative in different clinical settings. ADCC appears to be the prevalent mechanism in trastuzumab neoadjuvant monotherapy, whereas in neoadjuvant, adjuvant or metastatic settings in which trastuzumab is combined with chemotherapy, the relative role of ADCC is probably small, considering the compromising effects of chemotherapy on the immune cells that mediate this mechanism. In neoadjuvant and adjuvant settings involving concomitant use of trastuzumab and chemotherapy, the primary mechanism at play is presumably inhibition of DNA repair by the antibody, while in sequential protocols, the antibody acts mostly by exerting cytostatic activity through inhibition of HER2-mediated tumor cell proliferation. According to the ability of the antibody to induce cytotoxic or cytostatic antitumor effects depending on the clinical setting, different criteria, i.e., RECIST for cytotoxic effect, OS, and DFS for cytostatic, must be considered in accurately estimating antibody efficacy. Moreover, since trastuzumab resistance likely depends directly on the mechanisms responsible for its antitumor activity, resistance mechanisms must also be considered with respect to the different clinical settings.

Original languageEnglish
Pages (from-to)212-217
Number of pages6
JournalCancer Treatment Reviews
Volume38
Issue number3
DOIs
Publication statusPublished - May 2012

Fingerprint

Antibody-Dependent Cell Cytotoxicity
Cytostatic Agents
Antibodies
Drug Therapy
DNA Repair
Antibodies, Monoclonal, Humanized
Trastuzumab
Cell Proliferation
Breast Neoplasms
Neoplasms

Keywords

  • Breast cancer
  • HER2
  • Resistance
  • Response to therapy
  • Trastuzumab

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Activity and resistance of trastuzumab according to different clinical settings. / Tagliabue, Elda; Campiglio, Manuela; Pupa, Serenella M.; Ménard, Sylvie; Balsari, Andrea.

In: Cancer Treatment Reviews, Vol. 38, No. 3, 05.2012, p. 212-217.

Research output: Contribution to journalArticle

Tagliabue, Elda ; Campiglio, Manuela ; Pupa, Serenella M. ; Ménard, Sylvie ; Balsari, Andrea. / Activity and resistance of trastuzumab according to different clinical settings. In: Cancer Treatment Reviews. 2012 ; Vol. 38, No. 3. pp. 212-217.
@article{97065578fffc4db6b81ecd1fc0783ce3,
title = "Activity and resistance of trastuzumab according to different clinical settings",
abstract = "Trastuzumab, a humanized monoclonal antibody directed against HER2, has shown efficacy in breast cancers; however many patients do not respond to this reagent. Here, we discuss the potential mechanisms of trastuzumab efficacy and resistance in different clinical settings as a step toward optimizing the appropriate application of this antibody.The three major antitumor mechanisms of trastuzumab, i.e., inhibition of proliferation, antibody-dependent cell cytotoxicity (ADCC) and inhibition of DNA repair, appear to be differentially operative in different clinical settings. ADCC appears to be the prevalent mechanism in trastuzumab neoadjuvant monotherapy, whereas in neoadjuvant, adjuvant or metastatic settings in which trastuzumab is combined with chemotherapy, the relative role of ADCC is probably small, considering the compromising effects of chemotherapy on the immune cells that mediate this mechanism. In neoadjuvant and adjuvant settings involving concomitant use of trastuzumab and chemotherapy, the primary mechanism at play is presumably inhibition of DNA repair by the antibody, while in sequential protocols, the antibody acts mostly by exerting cytostatic activity through inhibition of HER2-mediated tumor cell proliferation. According to the ability of the antibody to induce cytotoxic or cytostatic antitumor effects depending on the clinical setting, different criteria, i.e., RECIST for cytotoxic effect, OS, and DFS for cytostatic, must be considered in accurately estimating antibody efficacy. Moreover, since trastuzumab resistance likely depends directly on the mechanisms responsible for its antitumor activity, resistance mechanisms must also be considered with respect to the different clinical settings.",
keywords = "Breast cancer, HER2, Resistance, Response to therapy, Trastuzumab",
author = "Elda Tagliabue and Manuela Campiglio and Pupa, {Serenella M.} and Sylvie M{\'e}nard and Andrea Balsari",
year = "2012",
month = "5",
doi = "10.1016/j.ctrv.2011.06.002",
language = "English",
volume = "38",
pages = "212--217",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Activity and resistance of trastuzumab according to different clinical settings

AU - Tagliabue, Elda

AU - Campiglio, Manuela

AU - Pupa, Serenella M.

AU - Ménard, Sylvie

AU - Balsari, Andrea

PY - 2012/5

Y1 - 2012/5

N2 - Trastuzumab, a humanized monoclonal antibody directed against HER2, has shown efficacy in breast cancers; however many patients do not respond to this reagent. Here, we discuss the potential mechanisms of trastuzumab efficacy and resistance in different clinical settings as a step toward optimizing the appropriate application of this antibody.The three major antitumor mechanisms of trastuzumab, i.e., inhibition of proliferation, antibody-dependent cell cytotoxicity (ADCC) and inhibition of DNA repair, appear to be differentially operative in different clinical settings. ADCC appears to be the prevalent mechanism in trastuzumab neoadjuvant monotherapy, whereas in neoadjuvant, adjuvant or metastatic settings in which trastuzumab is combined with chemotherapy, the relative role of ADCC is probably small, considering the compromising effects of chemotherapy on the immune cells that mediate this mechanism. In neoadjuvant and adjuvant settings involving concomitant use of trastuzumab and chemotherapy, the primary mechanism at play is presumably inhibition of DNA repair by the antibody, while in sequential protocols, the antibody acts mostly by exerting cytostatic activity through inhibition of HER2-mediated tumor cell proliferation. According to the ability of the antibody to induce cytotoxic or cytostatic antitumor effects depending on the clinical setting, different criteria, i.e., RECIST for cytotoxic effect, OS, and DFS for cytostatic, must be considered in accurately estimating antibody efficacy. Moreover, since trastuzumab resistance likely depends directly on the mechanisms responsible for its antitumor activity, resistance mechanisms must also be considered with respect to the different clinical settings.

AB - Trastuzumab, a humanized monoclonal antibody directed against HER2, has shown efficacy in breast cancers; however many patients do not respond to this reagent. Here, we discuss the potential mechanisms of trastuzumab efficacy and resistance in different clinical settings as a step toward optimizing the appropriate application of this antibody.The three major antitumor mechanisms of trastuzumab, i.e., inhibition of proliferation, antibody-dependent cell cytotoxicity (ADCC) and inhibition of DNA repair, appear to be differentially operative in different clinical settings. ADCC appears to be the prevalent mechanism in trastuzumab neoadjuvant monotherapy, whereas in neoadjuvant, adjuvant or metastatic settings in which trastuzumab is combined with chemotherapy, the relative role of ADCC is probably small, considering the compromising effects of chemotherapy on the immune cells that mediate this mechanism. In neoadjuvant and adjuvant settings involving concomitant use of trastuzumab and chemotherapy, the primary mechanism at play is presumably inhibition of DNA repair by the antibody, while in sequential protocols, the antibody acts mostly by exerting cytostatic activity through inhibition of HER2-mediated tumor cell proliferation. According to the ability of the antibody to induce cytotoxic or cytostatic antitumor effects depending on the clinical setting, different criteria, i.e., RECIST for cytotoxic effect, OS, and DFS for cytostatic, must be considered in accurately estimating antibody efficacy. Moreover, since trastuzumab resistance likely depends directly on the mechanisms responsible for its antitumor activity, resistance mechanisms must also be considered with respect to the different clinical settings.

KW - Breast cancer

KW - HER2

KW - Resistance

KW - Response to therapy

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=84857645689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857645689&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2011.06.002

DO - 10.1016/j.ctrv.2011.06.002

M3 - Article

C2 - 21726959

AN - SCOPUS:84857645689

VL - 38

SP - 212

EP - 217

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

IS - 3

ER -